Table 2. Baseline characteristics on the study cohort (n=261).
| Variables | Values |
|---|---|
| Gender, n (%) | |
| Male | 204 (78.2) |
| Female | 57 (21.8) |
| Age (years), mean (standard deviation) | 68 (7.0) |
| CACI, median [IQR] | 5 [4, 5] |
| NAC regimen, n (%) | |
| HD-MVAC/MVAC | 208 (79.7) |
| Other | 53 (20.3) |
| Carbo-Gem | 19 (7.2) |
| HD-MVEC | 14 (5.4) |
| Other | 20 (7.7) |
| NAC-cycles, mean (standard deviation) | |
| Total | 2.8 (0.9) |
| ≥3 | 3.2 (0.5) |
| <3 | 1.5 (0.6) |
| cT-stage, n (%) | |
| T2 | 169 (64.4) |
| T3 | 77 (29.5) |
| T4a | 15 (5.7) |
| Downstaging (pTNM), n (%) | |
| CR (pT0N0M0) | 84 (32.2) |
| PR (pTa, pTis, pT1N0M0) | 45 (17.2) |
| SD (pT2–4aN0M0) | 81 (31.0) |
| PD (pN+, pT4b) | 51 (19.5) |
CACI, Charlson Comorbidity Index; IQR, interquartile range; NAC, neoadjuvant chemotherapy; HD-MVAC, high-dose intensity methotrexate, vinblastine, adriamycin (doxorubicin) and cisplatin; MVAC, methotrexate, vinblastine, adriamycin (doxorubicin) and cisplatin; Carbo-Gem, carboplatin-gemcitabine; HD-MVEC, high-dose methotrexate/vinblastine/epirubicine/cisplatin; cT, clinical tumor; pTNM, pathological tumour-node-metastasis; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.